Longevity biotech startup NewLimit announced a $435 million Series C funding round in the early hours of June 3 (Beijing time). The round was led by Peter Thiel's Founders Fund, with continued participation from existing investors including Abstract Ventures, Kleiner Perkins, NFDG, Eli Lilly Ventures, and Valor Equity Partners, alongside new backers Thrive Capital, Greenoaks, and Quiet Capital. The Wall Street Journal reported that the round valued NewLimit at $3.1 billion, more than tripling its valuation from a year ago.
In its funding announcement, NewLimit revealed that breakthrough research has allowed the company to transition longevity medicine into human clinical trials. Its first drug candidate, targeting alcohol-related liver disease, is expected to enter clinical trials next year. The company stated, "By reprogramming cell age, humanity can achieve longer healthy lifespan. Now, we are closer than ever to the goal of slowing or even reversing aging."
NewLimit was co-founded by Coinbase founder and CEO Brian Armstrong. In 2021, Armstrong joined forces with former GV partner and bioengineer Blake Byers and stem cell biologist Jacob Kimmel to invest $110 million and launch NewLimit in South San Francisco. Prior to this Series C, the company had completed three earlier funding rounds.
The Science of Cellular Reprogramming
NewLimit aims to develop drugs that extend healthy lifespan, centered on reversing cellular functional decline. For decades, scientists recognized the link between aging and cellular degeneration, but precisely reversing cellular age remained elusive. That changed in 2006, when Japanese scientist Shinya Yamanaka discovered that activating just a few specific transcription factors could reprogram adult cells into a youthful, embryonic stem cell-like state. Dubbed "Yamanaka factors," this finding overturned the dogma that aging is irreversible and earned Yamanaka the 2012 Nobel Prize in Physiology or Medicine.
NewLimit's approach is built directly on this scientific foundation. According to its website, "Our medicines can reprogram the epigenome of cells to a younger state by activating specific transcription factor genes. We know this reversal is possible, but which combinations of transcription factors restore youthful function for different cell types remains unknown. Discovering these effective genetic payloads is the core challenge of our work."
Clinical Pathway via Liver Disease
NewLimit's strategy is to first target a specific disease, secure drug approval, and then expand into broader applications. The alcohol-related liver disease drug represents this initial focus. Co-founder and CEO Jacob Kimmel explained that liver disease can be viewed as an "accelerated version of aging," manifesting the same degenerative processes everyone experiences but in a faster and more severe form, making it an ideal model for testing cell reprogramming therapies.
The Billionaires' Immortality Race
NewLimit is not alone in the pursuit of radical life extension. In 2022, Sam Altman invested $180 million in Retro Biosciences, a company developing drugs to rejuvenate aging cells; its valuation reportedly reached $1.8 billion last month. Also in 2022, Altos Labs launched with a reported $3 billion in backing from Jeff Bezos and other investors, with cumulative funding now close to double that figure.
From Peter Thiel to Sam Altman to Jeff Bezos, the biggest backers of this space are invariably the ultra-wealthy at the apex of technology and finance. Thiel has publicly expressed an intense aversion to death, once stating, "Death is humanity's greatest enemy, yet we treat it as a natural law." For tech moguls who have achieved extreme wealth and power, time becomes the only remaining adversary — and the one luxury money cannot yet buy. That logic underpins why they are pouring billions into longevity science.